Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57433 | 1.00 | NFKB1 (0.32) | NFKB1NFKB2RELAGLO1HDAC6 | |
| SCHEMBL12202636 | 0.86 | NFKB1 (0.33) | NFKB1NFKB2RELAGLO1HDAC6 | |
| SCHEMBL57627 | 0.83 | TUBB1 (0.33) | AAK1TUBB1 | |
| SCHEMBL16169554 | 0.82 | TUBB1 (0.34) | GLO1CYP2C9CYP2D6CYP2C19TUBB1 | |
| SCHEMBL14210216 | 0.82 | TUBB1 (0.34) | GLO1CYP2C9CYP2D6CYP2C19TUBB1 | |
| SCHEMBL14210612 | 0.82 | GLO1 (0.34) | GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL6671670 | 0.82 | AAK1 (0.36) | NFKB1NFKB2RELAGLO1AAK1 | |
| SCHEMBL6671661 | 0.82 | AAK1 (0.36) | NFKB1NFKB2RELAGLO1AAK1 | |
| SCHEMBL12202580 | 0.81 | TUBB1 (0.41) | AAK1TUBB1 | |
| SCHEMBL4365675 | 0.81 | TUBB1 (0.41) | AAK1TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-10-22 | — | — | US | disclosed |
| US-7579323-B1 | Analogs of hemiasterlin wherein the indole moiety of hemiasterlin has been deleted or replaced demonstrate potent anti-mitotic and cytotoxic activity; may be useful in treatment of colon, breast, lung cancers | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | NUMA1, CYP11A1, PDS5A | NFKB1 2510/4885NFKB2 2364/4885RELA 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.